Yahoo
OTC Markets OTCPK - Delayed Quote USD

Nutra Pharma Corp. (NPHC)

0.0001 0.0000 (0.00%)
At close: 3:21:49 PM EST
Chart Range Bar
Loading chart for NPHC
  • Previous Close 0.0001
  • Open 0.0001
  • Bid 0.0001 x 1068030000
  • Ask 0.0070 x 19580000
  • Day's Range 0.0001 - 0.0001
  • 52 Week Range 0.0001 - 0.0050
  • Volume 195,800
  • Avg. Volume 177,749
  • Market Cap (intraday) 715,972
  • Beta (5Y Monthly) 65.25
  • PE Ratio (TTM) --
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, over–the–counter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti -viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Boca Raton, Florida.

www.nutrapharma.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NPHC
0.00%
S&P 500 (^GSPC)
7.76%

1-Year Return

NPHC
0.00%
S&P 500 (^GSPC)
9.77%

3-Year Return

NPHC
0.00%
S&P 500 (^GSPC)
68.96%

5-Year Return

NPHC
96.15%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY15
Revenue 52.87k
Earnings --
Profit Margin 0.00%

Q3

FY15

0
10K
20K
30K
40K
50K
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -138.05%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    258.91k

  • Net Income Avi to Common (ttm)

    -5.42M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.6k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    2.92M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: